J.P Morgan Healthcare
Conference
January 12th, 2022
Lupin Limited
Vinita Gupta, CEO
Safe Harbor Statement
Materials and information provided during this presentation may contain 'forward-looking statements'. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-relatedforward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents obtained by competitors. Challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation.
The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as | |
a result of new information, future events, or otherwise. | 2 |
Lupin Today
Financial Metrics | Globally | Major Markets | ||||||||||||||
10th | 6th | 3rd | 6th | 4th | 5th | 4th | ||||||||||
Market Cap (5) | US$ 5.7 bn | |||||||||||||||
Largest Generic | Largest Indian | Largest in | India Pharma | South Africa | Largest | Largest | ||||||||||
Revenue (FY21)(6) | US$ 2.0 bn | |||||||||||||||
company | Pharma | the US | 2 | Generic Rank | Branded Gx | Australia Gx | 4 | |||||||||
Market Rank | ||||||||||||||||
(by sales1) | (by global sales1) | (by prescriptions2) | (by prescriptions3) | Philippines4 | ||||||||||||
EBITDA (FY21)(6) | US$ 364 mn | |||||||||||||||
Netherlands | ||||||||||||||||
FY21 Revenues split | 1 | |||||||||||||||
US | 1 | |||||||||||||||
API | 2 | India | ||||||||||||||
9% | Mexico | 1 | 12 | |||||||||||||
1 | 2 |
India | North |
America | |
35% | |
37% | |
ROW | EMEA | Growth Markets |
2% | 8% | |
9% | ||
Brazil 1
1
20,500+ Global employees |
Products sold in 100 countries |
30 bn+ extended unit capacity |
Manufacturing
Research
15 | 7 | | API, Generics, Biologics, |
R&D | Specialty, NCE | ||
Mfg sites | | OSD, Injectables, Inhalation, | |
sites | |||
Ophthalmic, Derm, LARCs |
1. LTM sales as of 31st Mar 2021 |
3. IQVIA MAT Aug-21 |
5. As of January 7, 2022
3
2. IQVIA MAT Sep-21 |
4. IQVIA MAT Jun-21 |
6. Exchange rate used US$ 1 = INR 74.24 (Average for FY21)
CY21 Highlights and Recent Performance
Increasing Sales Momentum: Achieved sustained quarterly revenue growth despite headwinds
Complex Gx Platform Successes: Inhalation and Biosimilars platforms continued scaling
- Albuterol reached 20%+ US generic market share. Authorized generic launch of Brovana in the US reached 50% share. Luforbec, gFostair launched in the UK.
H1 FY20221
(% of Global Net Sales)
India, | North America, |
39% | 34% |
- bEtanercept sales continued to grow in Europe and Japan. US BLA filed on Pegfilgrastim.
Novel Pipeline Progress: Received USD 50 million development milestones from BI on MEK Inhibitor. Lupin Oncology Inc created to advance pipeline of differentiated Oncology programs.
R&D Spend
8.5%
Gx Pipeline Progress: 19 filings with the US FDA in CY21 incl. 4 eFTF, bringing our total FTFs to 51
NCE
EMEA, 7%
Rebuilding Quality Reputation: 17 positive outcomes on Major agency audits during CY20 & CY21 (USFDA, MHRA, PMDA, ANVISA, Cofepris)
income, 5% API, 6% Growth Markets, 8%
EBITDA Trend2
• | Received EIR from US FDA with Voluntary Action Indicated classification for Goa plant | 8000 | 18.6% | 18.8% | 2 | ||
• | Track record of success on desktop audits from WHO and TGA | 6000 | 14.7% | 16.8% | 14.3% | 14.9% | 1 |
EBITDA Focus: Focus on pipeline monetization and cost optimization to enhance EBITDA | 4000 | 1 | |||||
Navigating the COVID Era: Delivered our mission of ensuring the health and well-being of our | 2000 | 5. | |||||
0 | 0. | ||||||
people while maintaining our supply of life-saving medicines | Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 | ||||||
1. H1 FY22 is Apr-21 to Sept-21. Total Revenue and EBITDA Growth rate at USD, as previously reported | EBITDA | EBITDA % | 4 | ||||
2. Reported numbers excluding impact of FX, Other income and one time costs | Source: IQVIA MAT, Weekly NPA |
Strategic Vision: Evolving and Growing Global Pharma Company
Highly scaled and Evolving Core Generics Businesses
Innovative Platforms
Strong
Generics
Foundation
Amongst the Top 10 generic companies in the World
US Generics
Growth driven by a diversified portfolio
Execution on high- value opportunities
India Region Formulations
Achieving Top 3 by share and building in select adjacencies
Other Growth Markets
Grow Scale and Operating Leverage
Novel products: Specialty & NCE's
Canadian Specialty Platform
Focused Commercialization in GI (Zaxine) and Women's Health
EU Neurology
Evolving through Complex Generics
Investing heavily in the development of high barrier therapeutics
Global | Global | Global Long | ||
Inhalation | Biosimilars | Acting and US | ||
Platform | Business | Gx Injectables | ||
Execution and scaling | Launch execution, | Clinical execution | ||
in our markets and | Portfolio expansion | and Scale | ||
beyond | and Development | |||
Integrated Global Quality Culture
NaMuscla
Geographic expansion and partnership
US Women's Health
Targeted operations with accretive portfolio expansion
Novel Oncology Research Platform
Pipeline acceleration
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Lupin Limited published this content on 12 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2022 13:55:06 UTC.